News

HCT Tied to Long-Term Survival and Early Death in Certain Patients With MF

05/28/2020

Study findings suggest that there is a long-term survival advantage of allogeneic HCT in certain patients with MF, but at the expense of possible early death.

Study findings suggest that...

05/28/2020

Oncology

News

Hydroxyurea Use in Patients With PV Requires Active Monitoring, Management

04/17/2020

Active management is needed for patients with PV given hydroxyurea to maintain blood count control, with extra monitoring for signs and symptoms of hydroxyurea intolerance.

Active management is needed for...

04/17/2020

Oncology

News

FDA Approves Drug to Treat Anemia in Patients With MDS

04/07/2020

The FDA has approved luspatercept-aamt for the treatment of anemia in certain adults with MDS.

The FDA has approved...

04/07/2020

Oncology

News

Enasidenib Well-Tolerated, Active in Patients With IDH2-Mutated MDS

03/23/2020

Enasidenib was shown to be well-tolerated and clinically active in a study of patients with relapsed or refractory IDH2-mutated MDS.

Enasidenib was shown to be...

03/23/2020

Oncology

News

Risk for Vascular Complications Greatly Affects Life Expectancy in ET and PV

03/19/2020

The risk for vascular complications among patients with ET and PV are high, and these complications pose a considerable threat on life expectancy.

The risk for vascular...

03/19/2020

Oncology

News

Fludarabine–Treosulfan Conditioning Combo Improves Post-Transplant Outcomes in MDS

03/04/2020

Standard myeloablative conditioning before allo-HSCT is significantly inferior to conditioning with fludarabine and treosulfan in patients with MDS.

Standard myeloablative...

03/04/2020

Oncology

News

Long-Term Ropeginterferon Alfa-2b Safe, Effective for Polycythemia Vera

02/27/2020

Ropeginterferon alfa-2b induces high and durable hematologic and molecular responses and demonstrates improved responses over time over hydroxyurea in PV.

Ropeginterferon alfa-2b induces...

02/27/2020

Oncology

News

Researchers Identify Prognostic Factors in TP53-Mutated MDS

02/24/2020

A retrospective study finds karyotypic complexity and TP53 variant allele frequency can define prognostic subgroups in TP53-mutated MDS and TP53 VAF helps predict survival outcomes to treatment.

A retrospective study finds...

02/24/2020

Oncology

News

Long-Term Ruxolitinib Safe, Effective for Polycythemia Vera

02/12/2020

Long-term results from the RESPONSE trial show that ruxolitinib is a safe and effective therapy option for patients with PV resistant to or intolerant of hydroxyurea.

Long-term results from the...

02/12/2020

Oncology

News

Ruxolitinib Combo Therapy Reduces Symptom Burden in Patients With PV, MF

01/22/2020

In patients with PV and MF, ruxolitinib therapy plus low-dose PEG-IFNα2 improved cell counts and reduced symptom burden with acceptable toxicity.

In patients with PV and MF,...

01/22/2020

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology